Summary of All Reports

1. Complete Blood Count (CBC) - Lakhimpur Medical College, 01/07/2026

• Moderate microcytic, hypochromic anemia (Hgb 8.5, MCV 62, MCH 19, MCHC 30.6)
• Significant anisocytosis (RDW-CV 21.1%) - red cells are highly variable in size
• Eosinophilia (8.4%) - possible parasitic infection, allergic process, or related to hemoglobinopathy
• Mild thrombocytopenia (platelets 114)
• The machine flagged: Anisocytosis, Microcytosis, Anemia, and queried "Iron Deficiency?"

2. Hemoglobin Typing (HPLC) - Lakhimpur Medical College

• Hb E Disease (homozygous) is a thalassemia-like hemoglobin disorder very common in Northeast India and Southeast Asia
• Patients typically have mild to moderate microcytic anemia - exactly matching this CBC
• The extremely low MCV (62.2 fL) and low MCH are classic features
• The report itself states: "Chromatogram is suggestive of Hb E/E (homozygous)" - Diagnosis: Hb E Disease
• The lab correctly advises DNA study for confirmation and parental screening

This explains the CBC picture - the "Iron Deficiency?" flag from the machine is misleading here; the microcytosis is due to Hb E disease, not iron deficiency (though coexistent iron deficiency cannot be excluded without serum ferritin/iron studies).

3. Widal Test - Saumerpith Hospital, 09/07/2026

4. Serology Panel - Lakhimpur Medical College (Microbiology Dept.)

5. VDRL & HIV (Billing Receipt from Saumerpith)

6. Doctor's Prescription - Dr. Milon Kumar Taye (OBS & Gynae, 02/06/2026)

• Presenting complaint: Weakness
• Amenorrhea from 04/04/2026 to 27/06/2026 (approximately 3 months of absent periods)
• Previous blood transfusion on 11/06/2026 when Hgb was 6.38 g/dL (severely anemic at that point)

• Wt: 50 kg, Pulse: 68/min, BP: 110/70 mmHg
• Pallor present
• Oedema: Absent, Icterus: Absent
• Abdomen: Liver not palpable, Spleen not palpable

• Tab. Cifran (Ciprofloxacin) - 03 tablets
• Tab. Baxter 500mg - 10 tablets
• Sig: One tablet twice daily after a meal × 5 days (1-0-1)

Overall Clinical Summary

1. Homozygous Hemoglobin E Disease (Hb E/E) - the primary diagnosis explaining her chronic microcytic hypochromic anemia
2. Moderate anemia (Hgb 8.5 g/dL) with microcytosis, consistent with Hb E disease; she previously required a blood transfusion when Hgb dropped to 6.38 g/dL
3. Mild thrombocytopenia (PLT 114) - may be related to hypersplenism (though spleen was clinically not palpable) or another cause
4. Eosinophilia - warrants attention; could suggest helminthic infestation, which is common in this region and can worsen anemia
5. No typhoid, hepatitis B, hepatitis C detected
6. Amenorrhea (3 months) in the context of severe anemia - likely anemia-related anovulation
7. No organomegaly on clinical exam

• DNA molecular testing to confirm Hb E/E genotype
• Parental/family screening for Hb E carrier status
• Serum ferritin and iron studies to rule out coexistent iron deficiency anemia (which is treatable and common)
• Stool examination for ova and parasites given eosinophilia
• Follow-up Hgb levels to determine if transfusion support is needed again

Important note: This interpretation is for informational purposes. All findings should be discussed with her treating physician (Dr. M.K. Taye) for clinical correlation and management decisions.

Management of Homozygous Hb E Disease

Understanding Her Clinical Position

1. Immediate Priorities

A. Rule Out Coexistent Iron Deficiency

• Serum ferritin (most reliable single test)
• Serum iron + TIBC + transferrin saturation
• Peripheral blood smear for target cells, poikilocytosis

If ferritin is low - she has coexistent iron deficiency which is treatable and explains why her Hgb (8.5) is lower than expected for pure Hb EE (typically 9-11 g/dL). Oral iron supplementation would then be appropriate. If ferritin is normal or high - do NOT give iron (iron overload is a real risk in thalassemia patients).

B. Address Eosinophilia (8.4%)

• Stool exam for ova and parasites (hookworm, roundworm are common in Assam and contribute to iron loss/anemia)
• Treat helminthic infestation if found (Tab. Albendazole 400 mg single dose)

2. Supportive Pharmacotherapy

Folic Acid Supplementation (MAINSTAY)

• Folic acid 5 mg/day orally - standard for all thalassemic conditions
• Rationale: chronic hemolysis increases folate demand; megaloblastic change can worsen anemia
• Continue indefinitely
• Goldman-Cecil Medicine confirms folic acid is routinely given in HbH and thalassemia intermedia conditions (2-5 mg/day)

Iron Supplementation

• Give only if iron deficiency is confirmed by serum ferritin < 12 ng/mL
• If given, monitor ferritin to avoid overload
• Do NOT empirically prescribe iron in thalassemia patients

3. Blood Transfusion - When to Transfuse

• Symptomatic anemia (severe fatigue, dyspnea, cardiac symptoms) with Hgb < 7 g/dL
• Hgb < 6 g/dL regardless of symptoms
• Growth failure, developmental delay (not applicable here)
• Pregnancy (discussed below)
• Aplastic crisis during infection

4. Monitor for Iron Overload

• Each unit of packed RBCs delivers ~200-250 mg of iron
• Hb E patients also have increased gastrointestinal iron absorption due to ineffective erythropoiesis

• Serum ferritin every 6-12 months
• Liver iron concentration (MRI T2*) if ferritin > 800 ng/mL

• Deferasirox (Exjade/Asunra) 10-20 mg/kg/day orally - preferred oral agent, also indicated for NTDT per Goodman & Gilman's
• Deferoxamine - subcutaneous infusion, older agent
• Deferiprone - oral, used in some settings

5. Manage Amenorrhea

• Chronic anemia impairs GnRH pulsatility → anovulation → amenorrhea
• As Hgb improves with treatment, cycles typically resume
• Dr. Taye (OBS/Gynae) is the right specialist to manage this
• Rule out pregnancy first (urine/serum beta-hCG)
• If cycles don't resume after Hgb correction, consider hormonal evaluation (FSH, LH, prolactin, thyroid)

6. Genetic Counseling (Critical)

• Both her children must be screened for Hb E trait (Hb AE) or Hb EE
• Her husband should be tested for hemoglobin typing
• If husband is Hb E carrier (Hb AE): 25% chance each child gets Hb EE
• If husband is beta-thalassemia carrier: risk of severe Hb E/beta-thalassemia in offspring (can be as severe as thalassemia major requiring lifelong transfusions)
• DNA molecular testing for her - as recommended by the lab - to confirm exact genotype and guide family counseling
• Refer to a medical geneticist or hemoglobinopathy clinic

7. Monitoring Schedule

8. Advanced Therapy (Future Consideration)

• Hydroxyurea - increases HbF production, can raise Hgb and reduce transfusion need in some thalassemia syndromes. Evidence in pure Hb EE is modest but it is used in Hb E/beta-thalassemia. Worth discussing with a hematologist if anemia remains symptomatic.
• Luspatercept (Reblozyl) - erythroid maturation agent approved for non-transfusion dependent thalassemia (beta-thalassemia) in adults; evidence specifically for Hb EE is emerging.
• Hematopoietic Stem Cell Transplant (HSCT) - only if she progresses to a severe transfusion-dependent phenotype; curative but requires HLA-matched donor.
• Gene therapy - still in trials; not currently available in this setting.

9. Current Prescription by Dr. Taye

• Tab. Cifran (Ciprofloxacin) + Tab. Baxter (likely Metronidazole 500 mg) - twice daily for 5 days

Summary Algorithm for This Patient

Hb EE, Hgb 8.5 g/dL
        ↓
1. Folic acid 5 mg/day (start immediately)
2. Check ferritin → if low → oral iron; if normal → no iron
3. Stool exam → if parasites → Albendazole
4. Rule out pregnancy (amenorrhea)
5. Husband + family Hb typing + genetic counseling
6. DNA study for confirmation (as lab advised)
7. Quarterly Hgb monitoring
8. Transfuse only if Hgb < 7 with symptoms
9. Monitor ferritin for iron overload
10. If ferritin > 1000 → iron chelation (Deferasirox)

All management decisions should be confirmed with her treating team - Dr. M.K. Taye (OBS/Gynae) for the amenorrhea and a Hematologist for the Hb E disease. A combined specialist approach is ideal for this patient.

Surgical Intervention - Is It Required?

Short Answer: No surgical intervention is currently indicated.

Evidence From Her Reports

1. Spleen - Not Palpable

"Sp/ not palpable" (Spleen not palpable)

• No splenomegaly = no hypersplenism = no indication for splenectomy at this time
• Her thrombocytopenia (PLT 114) is mild and likely related to the hemoglobinopathy itself, not hypersplenism requiring surgery

2. Liver - Not Palpable

"Liver not palpable"

• No hepatomegaly
• No portal hypertension signs
• No hepatic surgical concern

3. No Transfusion Burden Heavy Enough to Justify Splenectomy

• Annual blood consumption rises progressively despite good chelation
• Transfusion requirement > 200-220 mL/kg/year of packed RBCs
• She is far from meeting these thresholds

4. No Acute Abdomen / Surgical Emergency

• No oedema, no icterus
• No abdominal pain documented
• Infection markers (Widal, HBsAg, HCV, HIV) all negative
• No evidence of gallstones (common complication of chronic hemolysis - but not yet documented / not tested)

5. Amenorrhea - Not Surgical

• Fibroids requiring myomectomy
• Ovarian pathology
• Ectopic pregnancy These would need ultrasound/imaging to rule out completely, but nothing in the current reports points to a surgical gynaecological cause.

What to Watch For - Future Surgical Triggers

One Recommendation

• To screen for gallstones (silent in early stages, very common in chronic hemolysis)
• To get a baseline measurement of spleen and liver size for future comparison
• To investigate the amenorrhea (rule out uterine/ovarian pathology)

Bottom Line

Mrs. Annada Chutia does not require any surgical intervention based on current reports. Her condition is medical, not surgical. The priority is folic acid supplementation, ferritin-guided iron management, anti-helminthic treatment if parasites found, genetic counseling, and close hematological follow-up.